Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation

Journal of Clinical Investigation

Volumn 116, Issue 8, 2006, Pages 2105-2114

  Wang, Honglin ^a   Peters, Thorsten ^a   Kess, Daniel ^a   Sindrilaru, Anca ^a   Oreshkova, Tsvetelina ^a   Van Rooijen, Nico ^b   Stratis, Athanasios ^c   Renkl, Andreas C ^a   Sunderkötter, Cord ^a   Wlaschek, Meinhard ^a   Haase, Ingo ^c   Scharffetter Kochanek, Karin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CHEMOTACTIC PEPTIDE; ETANERCEPT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; IN VIVO STUDY; LYMPH NODE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PSORIASIS; SKIN INFLAMMATION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD11; ANTIGENS, CD18; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; INFLAMMATION; MACROPHAGE ACTIVATION; MICE; MICE, INBRED STRAINS; MUTATION; PHENOTYPE; PSORIASIS; RECOMBINANT PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 33746766314     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27180     Document Type: Article

References (62)

1. Nickoloff, B.J. 1999. The immunologic and genetic basis of psoriasis. Arch. Dermatol. 135:1104-1110.
2. Nickoloff, B.J., and Nestle, F.O. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113:1664-1675. doi:10.1172/JCI200422147.
3. Gillitzer, R., et al. 1993. MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J. Invest. Dermatol. 101:127-131.
4. van den Oord, J.J., and de Wolf-Peeters, C. 1994. Epithelium-lining macrophages in psoriasis. Br. J. Dermatol. 130:589-594.
5. Djemadji-Oudjiel, N., Goerdt, S., Kodelja, V., Schmuth, M., and Orfanos, C.E. 1996. Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis. Arch. Dermatol. Res. 288:757-764.
6. Antoni, C., and Manger, B. 2002. Infliximab for psoriasis and psoriatic arthritis. Clin. Exp. Rheumatol. 20(6 Suppl. 28):S122-S125.
7. Wakefield, P.E., James, W.D., Samlaska, C.P., and Meltzer, M.S. 1991. Tumor necrosis factor. J. Am. Acad. Dermatol. 24:675-685.
8. Nickoloff, B.J. 1991. The cytokine network in psoriasis. Arch. Dermatol. 127:871-884.
9. Leonardi, C.L., et al. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349:2014-2022.
10. Gottlieb, A.B., et al. 2005. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175:2721-2729.
11. Sano, S., et al. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11:43-49.
12. Schon, M.P., Detmar, M., and Parker, C.M. 1997. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat. Med. 3:183-188.
13. Pasparakis, M., et al. 2002. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature. 417:861-866.
14. Zenz, R., et al. 2005. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 437:369-375.
15. Wilson, R.W., et al. 1993. Gene targeting yields a CD18-mutant mouse for study of inflammation. J. Immunol. 151:1571-1578.
16. Bullard, D.C., et al. 1996. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93:2116-2121.
17. Shuster, S. 1972. Psoriatic alopecia. Br. J. Dermatol. 87:73-77.
18. Schon, M.P., and Boehncke, W.H. 2005. Psoriasis. N. Engl. J. Med. 352:1899-1912.
19. Feldman, S.R., et al. 2001. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J. Cutan. Med. Surg. 5:386-389.
20. van de Kerkhof, P.C., and Franssen, M.E. 2001. Psoriasis of the scalp. Diagnosis and management. Am. J. Clin. Dermatol. 2:159-165.
21. Kess, D., et al. 2003. CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J. Immunol. 171:5697-5706.
22. Morel, P., et al. 1992. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J. Autoimmun. 5:465-477.
23. Hynes, R.O. 1987. Integrins: a family of cell surface receptors. Cell. 48:549-554.
24. Carlos, T.M., and Harlan, J.M. 1994. Leukocyte-endothelial adhesion molecules. Blood. 84:2068-2101.
25. Grabbe, S., et al. 2002. β2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J. Clin. Invest. 109:183-192. doi:10.1172/JCI200211703.
26. Fine, J.S., and Kruisbeek, A.M. 1991. The role of LFA-1/ICAM-1 interactions during murine T lymphocyte development. J. Immunol. 147:2852-2859.
27. Quddus, J., Kaplan, A., and Richardson, B.C. 1994. Anti-CD11a prevents deletion of self-reactive T cells in neonatal C57BR mice. Immunology. 82:301-305.
28. van de Kerkhof, P.C., and Weemaes, C.M. 1990. Skin manifestations in congenital deficiency of leucocyte-adherence glycoproteins (CDLG). Br. J. Dermatol. 123:395-401.
29. Tomfohrde, J., et al. 1994. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 264:1141-1145.
30. Gencik, M., et al. 2000. The association of CD18 alleles with anti-myeloperoxidase subtypes of ANCA-associated systemic vasculitides. Clin. Immunol. 94:9-12.
31. Meller, S., et al. 2001. Novel SNPs in the CD18 gene validate the association with MPO-ANCA+ vasculitis. Genes Immun. 2:269-272.
32. Elliott, M.J., et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1105-1110.
33. van Roon, J.A., Lafeber, F.P., and Bijlsma, J.W. 2001. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 44:3-12.
34. Thepen, T., et al. 2000. Resolution of cutaneous inflammation after local elimination of macrophages. Nat. Biotechnol. 18:48-51.
35. Kurimoto, I., van Rooijen, N., Dijkstra, C.D., and Streilein, J.W. 1994. Role of phagocytic macrophages in induction of contact hypersensitivity and tolerance by hapten applied to normal and ultraviolet B-irradiated skin. Immunology. 83:281-287.
36. Van Rooijen, N., Kors, N., vd Ende, M., and Dijkstra, C.D. 1990. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res. 260:215-222.
37. Van Rooijen, N., and van Kesteren-Hendrikx, E. 2003. "In vivo" depletion of macrophages by liposome-mediated "suicide". Methods Enzymol. 373:3-16.
38. Sunderkötter, C., et al. 2004. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172:4410-4417.
39. Dupasquier, M., Stoitzner, P., van Oudenaren, A., Romani, N., and Leenen, P.J. 2004. Macrophages and dendritic cells constitute a major subpopulation of cells in the mouse dermis. J. Invest. Dermatol. 123:876-879.
40. Lu, B., et al. 1998. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187:601-608.
41. Nickoloff, B.J. 2000. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J. Investig. Dermatol. Symp. Proc. 5:67-73.
42. Vestergaard, C., et al. 2004. Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta Derm. Venereol. 84:353-358.
43. Drevets, D.A., et al. 2004. The Ly-6Chigh monocyte subpopulation transports Listeria monocytogenes into the brain during systemic infection of mice. J. Immunol. 172:4418-4424.
44. Grewal, I.S., et al. 1997. Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. J. Immunol. 159:401-408.
45. Nakamura, K., Williams, I.R., and Kupper, T.S. 1995. Keratinocyte-derived monocyte chemoattractant protein 1 (MCP-1): analysis in a transgenic model demonstrates MCP-1 can recruit dendritic and Langerhans cells to skin. J. Invest. Dermatol. 105:635-643.
46. Stout, R.D., and Suttles, J. 1993. T cell-macrophage cognate interaction in the activation of macrophage effector function by Th2 cells. J. Immunol. 150:5330-5337.
47. Schlaak, J.F., et al. 1994. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102:145-149.
48. Ackermann, L., and Harvima, I.T. 1998. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch. Dermatol. Res. 290:353-359.
49. Xaus, J., et al. 2000. LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-alpha. Blood. 95:3823-3831.
50. Ghoreschi, K., et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:40-46.
51. Trepicchio, W.L., et al. 1999. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104:1527-1537.
52. Kauffman, C.L., et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123:1037-1044.
53. Palladino, M.A., Bahjat, F.R., Theodorakis, E.A., and Moldawer, L.L. 2003. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2:736-746.
54. Ozawa, M., and Aiba, S. 2004. Immunopathogenesis of psoriasis. Curr. Drug Targets Inflamm. Allergy. 3:137-144.
55. Stratis, A., et al. 2006. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J. Clin. Invest. 116:2094-2104. doi:10.1172/JCI27179.
56. Ellis, C.N., and Krueger, G.G. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345:248-255.
57. Li, A.G., Wang, D., Feng, X.H., and Wang, X.J. 2004. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J. 23:1770-1781.
58. Nickoloff, B.J. 2006. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol. Med. 12:102-106.
59. Miller, R.A. 1982. The Koebner phenomenon. Int. J. Dermatol. 21:192-197.
60. Van Rooijen, N., and Sanders, A. 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods. 174:83-93.
61. Kraal, G., Rep, M., and Janse, M. 1987. Macrophages in T and B cell compartments and other tissue macrophages recognized by monoclonal antibody MOMA-2. An immunohistochemical study. Scand. J. Immunol. 26:653-661.
62. Shinozaki, M., et al. 2002. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J. Clin. Invest. 109:951-960. doi:10.1172/JCI200214574.